Abstract: A method for double-stranded DNA purification, by which a solution containing DNA in a mixture with other components is passed over a support on which is covalently coupled an oligonucleotide capable of hybridizing with a specific sequence present on the DNA to form a triple helix.

Abstract: Method for double-stranded DNA purification, by which a solution containing said DNA in a mixture with other components is passed over a support on which is covalently coupled in oligonucleotide capable of hybridizing with a specific sequence present on said DNA to form a triple helix.

Abstract: A method for double-stranded DNA purification, by which a solution containing DNA in a mixture with other components is passed over a support on which is covalently coupled an oligonucleotide capable of hybridizing with a specific sequence present on the DNA to form a triple helix.

Abstract: A circular DNA molecule, useful for gene therapy, comprising at least one nucleic acid sequence of interest, characterised in that the region allowing the replication thereof has an origin of replication with a functionality in a host cell that requires the presence of at least one specific protein foreign to said host cell. A method for preparing same, cells incorporating said DNA molecules and uses thereof in gene therapy are also described.

Abstract: The invention relates to modified soluble FGF receptor Fc fusions comprising a fusion of a soluble fragment or domain of the FGF receptor part (targeting or binding moiety) with an Fc region of an immunoglobulin part (effector function moiety), having improved biological activity including ADCC/CDC activities, compositions containing them, and method of producing such modified soluble FGF receptor Fc fusion molecules.

Abstract: Method for double-stranded DNA purification, by which a solution containing said DNA in a mixture with other components is passed over a support on which is covalently coupled in oligonucleotide capable of hybridizing with a specific sequence present on said DNA to form a triple helix.

Abstract: A method for double-stranded DNA purification, by which a solution containing DNA in a mixture with other components is passed over a support on which is covalently coupled an oligonucleotide capable of hybridizing with a specific sequence present on the DNA to form a triple helix.

Abstract: The present invention relates to novel target double-stranded DNA sequences capable of interacting with a third strand and of forming a stable triple helix. The present invention also relates to a process for purifying a double-stranded DNA molecule, according to which a solution containing said DNA molecule is brought into contact with a third DNA strand capable of forming, by hybridization, a triple helix structure with a target double-stranded DNA sequence carried by said DNA molecule.

Abstract: A prokaryotic recombinant host cell comprising a heterologous replication initiation protein that activates a conditional origin of replication and an extrachromosomal DNA molecule comprising a heterologous therapeutic gene and a conditional origin of replication whose functionality in the prokaryotic recombinant host cell requires a replication initiating protein which is foreign to the host cell is described. The host cell may comprise a pir gene having at least one mutation, which may occur in the pir gene copy number control region, the pir gene leucine zipper-like motif, or the pir gene DNA binding region.

Abstract: A circular DNA molecule, useful for gene therapy, comprising at least one nucleic acid sequence of interest, characterised in that the region allowing the replication thereof has an origin of replication with a functionality in a host cell that requires the presence of at least one specific protein foreign to said host cell. A method for preparing same, cells incorporating said DNA molecules and uses thereof in gene therapy are also described.

Abstract: This invention provides a process for the continuous alkaline lysis of a bacterial suspension in order to harvest pDNA. It further provides for optional additional purification steps, including lysate filtration, anion exchange chromatography, triplex affinity chromatogragphy, and hydrophobic interaction chromatography. These optional purification steps can be combined with the continuous lysis in order to produce a highly purified pDNA product substantially free of gDNA, RNA, protein, endotoxin, and other contaminants.

Abstract: A circular DNA molecule, useful for gene therapy, comprising at least one nucleic acid sequence of interest, characterised in that the region allowing the replication thereof has an origin of replication with a functionality in a host cell that requires the presence of at least one specific protein foreign to said host cell. A method for preparing same, cells incorporating said DNA molecules and uses thereof in gene therapy are also described.

Abstract: Liquid or frozen compositions containing adenoviral-particles, comprising a buffer solution capable of maintaining the pH of the medium at slightly alkaline values, supplemented with glycerol and without addition of divalent metal cations or of alkali metal cations.

Abstract: The invention relates to novel promoter sequences derived from a portion upstream of the coding sequence of the gene for the CARP protein (Cardiac Ankyrin Repeat Protein), and which are capable of controlling the level and the specificity of expression of a transgene in vivo in cardiac muscle cells. The invention thus describes novel compositions, constructs, vectors and their uses in vivo for the transfer and expression of a nucleic acid in vivo in cardiac muscle cells. The subject of the present invention is also the use of the promoter sequences for generating transgenic animals which constitute models for studying certain cardiac pathologies.

Abstract: The invention concerns novel methods and constructs for controlling nucleic acid expression, in particular methods and constructs using NRSE sequences for obtaining a targeted expression of transgenes in nerve cells.

Abstract: The present invention relates to novel target double-stranded DNA sequences capable of interacting with a third strand and of forming a stable triple helix. The present invention also relates to a process for purifying a double-stranded DNA molecule, according to which a solution containing said DNA molecule is brought into contact with a third DNA strand capable of forming, by hybridization, a triple helix structure with a target double-stranded DNA sequence carried by said DNA molecule.

Abstract: Method for double-stranded DNA purification, by which a solution containing said DNA in a mixture with other components is passed over a support on which is covalently coupled in oligonucleotide capable of hybridizing with a specific sequence present on said DNA to form a triple helix.

Abstract: Method for double-stranded DNA purification, by which a solution containing said DNA in a mixture with other components is passed over a support on which is covalently coupled in oligonucleotide capable of hybridizing with a specific sequence present on said DNA to form a triple helix.

Abstract: The present invention relates to nucleic acids that encode novel basic helix-loop-helix polypeptides. The present invention also relates to novel basic helix-loop-helix polypeptides, in particular, rat Relax and human ngn3 polypeptides. The invention also relates to methods for the detection of nucleic acids and polypeptides according to the invention. The invention also relates to methods for the detection of activators or inhibitors of the polypeptides of the invention. Finally, the present invention relates to methods of prevention and/or treatment of pathologies, dysfunctions, disorders or conditions affecting the nervous system.

Abstract: The present invention relates to variants of TRAF2 which demonstrate the ability to inhibit the TNF ? signaling path-way. In particular, applicants have isolated a splice variant of TRAF2 referred to hereinafter as “TRAF2 truncated” or “TRAF2TR” and a TRAF2 expression construct with enhanced dominant negative properties, hereafter referred to as “TRAF2 truncated-deleted” or “TRAF2TD”. Both TRAF2TR and TRAF2TD have the ability to inhibit the TNF ? signaling pathway and in TRAF2TD, this ability is greatly enhanced, greatly reducing the response to TNF ? binding.